Literature DB >> 18639473

Isoforms of hyaluronidases can be a predictor of a prostate cancer of good prognosis.

Vanessa K de Sá1, Flávio C Canavez, Iran A Silva, Miguel Srougi, Katia R M Leite.   

Abstract

INTRODUCTION: Hyaluronidases (HAases) are enzymes related to cancer progression. Isoforms of HAases have been described as products of alternative splicing responsible for differences in enzyme activity. The heterogeneity of HAase expression has been identified in tumors and could be related to the differences in their biological behavior.
METHODS: Thirty-seven patients subjected to radical prostatectomy for prostate cancer were divided into 2 groups for the analyses: Low (< or =6-18) and high (> or =7-19) Gleason score and tumor behavior; recurrence 15 and nonrecurrence 22, mean follow-up 52.6 months.
CONCLUSION: A profile of HAase related to low Gleason score and non-tumor recurrence was characterized by expression of HYAL3-v1, HYAL1-v3, and HYAL3-v2. More studies should be made in order to confirm with larger series.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639473     DOI: 10.1016/j.urolonc.2008.04.013

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  3 in total

Review 1.  Emerging roles for hyaluronidase in cancer metastasis and therapy.

Authors:  Caitlin O McAtee; Joseph J Barycki; Melanie A Simpson
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

2.  Molecular cloning of a hyaluronidase from Bothrops pauloensis venom gland.

Authors:  Letícia Eulalio Castanheira; Renata Santos Rodrigues; Johara Boldrini-França; Fernando Pp Fonseca; Flávio Henrique-Silva; Maria I Homsi-Brandeburgo; Veridiana M Rodrigues
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2014-06-10

Review 3.  Molecular environment and atypical function: What do we know about enzymes associated with Mucopolysaccharidoses?

Authors:  Weijing Kong; Cheng Lu; Yingxue Ding; Yan Meng
Journal:  Orphanet J Rare Dis       Date:  2022-03-04       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.